Board of Directors​

Kung-Yee Liang, Ph.D.

Chairman

Heidi Wang, Ph. D.

Director and Chief Executive Officer

Tamon Tseng, LL.M.

Director

Wan-Fang Ting

Director

Howard S. Lee, Ph.D.

Independent Director

Chin-Ting Chiu

Independent Director

Dr. TAI-TSANG CHEN

Independent Director

Organization and responsibilities of the Board of Directors

The Board of Directors of OBI Pharma, Inc. is composed of six internationally renowned directors in various professional fields such as new drug research and development, biostatistics, law, international trade, accounting, etc., who are not only experienced and educated, but also have an international outlook, a broad vision, and insight into the current situation to ensure the direction and level of the company’s operation. 
Under the leadership of the Chairman, the Board of Directors of OBI Pharma, Inc. takes “integrity and social responsibility” as the core, and is responsible for counseling, supervising and evaluating the effective operation of the company’s management team and various departments. Internally, we strive to comply with laws and regulations and self-examine ourselves with the highest ethical standards, and set up various functional committees and audit offices such as audit and remuneration to implement the internal control system; Seek financial transparency and real-time disclosure of important information to protect the rights and interests of investors and fulfill corporate social responsibility. 

In addition, the external performance evaluation of the Board of Directors is conducted every three years, and the most recent performance evaluation of the Board of Directors was conducted by the China Corporate Governance Association, an external organization, for the period from January 1, 2021 to December 31, 2021. The performance evaluation of the board of directors of the organization is based on eight aspects, including the composition of the board of directors, guidance, delegation, supervision, communication, internal control and risk management, and self-discipline and other aspects of the board of directors. The evaluation method is based on questionnaires and company self-assessment, and the association reviews the relevant documents provided by the Company for review in writing, and interviews the chairman, independent directors and chief financial officer of the Company on February 14, 2022, to assist the Company in improving through the interaction and sharing of the evaluation process. The Board of Directors performance evaluation report was submitted on February 22, 2022, and the Company reported the results of the Board of Directors on March 18, 2022

Communication between independent directors and the head of internal audit and accountants

  1. The Company’s internal audit supervisor regularly communicates with the members of the Audit Committee the results of the audit report, and makes an internal audit report at the quarterly Audit Committee meeting, and reports to the members of the Audit Committee immediately if there is any special situation. There were no such special circumstances in the current year. The communication between the Audit Committee and the Head of Internal Audit of the Company is in good condition.
  2. The Company’s certified public accountants shall report the results of the audit of the financial statements and other communication matters required by relevant laws and regulations to the Audit Committee on a quarterly basis, and will report to the members of the Audit Committee immediately if there are any special circumstances, and there are no such special circumstances in the current year. The Company’s Audit Committee is in good communication with the certified public Accountants. 

Board Resolutions

2025-03-10 - The 23th of the 7th session
  1. Approved proposal for the Final Statement of 2024.
  2. Approved proposal for the Loss Allowance of 2024.
  3. Approved proposal for Recognizing the Internal Control System Statement of 2024.
  4. Approved responses the Company has planned for various scenarios to the potential recommendations from the DSMB regarding the second interim analysis of the AdaSim (OBI-822) Phase 3 clinical trial for triple-negative breast cancer.
  5. Approved reassignment of the Company’s representative to serve as an institutional director of the subsidiary, OBIGEN Pharma, Inc.
  6. Approved proposal of capital increase for the Australian subsidiary to support the Company’s clinical trial operations.
  7. Approved partial amendment of the Company’s Articles of Incorporation.
  8. Approved definition of the scope of entry-level employees of the Company for 2025.
  9. Approved change of custodian of the company seal in response to organizational adjustments.
  10. Approved election for the 8th Board of Directors.
  11. Approved the nomination period, number of positions to be elected, and the receiving location of candidates for the Board of Directors (including independent directors).
  12. Approved the establishment of the period and location for accepting shareholder proposals.
  13. Approved proposal for determining the date, place, and resolutions of the General Shareholders’ Meeting of 2025.
  14. Approved promotion of the Company’s Director of Medicinal Chemistry Department.
  15. Approved promotion of the Company’s Deputy Director of Business Department.
  16. Approved the remuneration evaluation and adjustment proposal for executives of the Company and its US subsidiary for 2025.
  17. Approved the incentive bonus distribution proposal for achieving the company’s goals for the year 2024.
  18. Approved the Company’s proposal for the first issuance roster of employee stock options for 2025.
2025-05-12 - The 24th of the 7th session
  1. Approved the Company’s Consolidated Financial Statement of the 1st quarter of 2025.
  2. Approved the termination of OBI-833.
  3. Approved the issuance of new common shares by private placement in cash.
  4. Approved amendment of the Company’s Audit Committee organizational regulations and operational management procedures and re-named as Audit and Risk Management Committee.
  5. Approved amendment of the Company’s Remuneration Committee organizational regulations and operational management procedures and re-named as Remuneration and Nomination Committee.
  6. Approved establishment of the Company’s Sustainable Development Committee organizational regulations.
  7. Approved nomination for candidates of directors and independent directors of the Board.
  8. Approved proposal to lift the non-competition restrictions for directors.
  9. Approved additional matters for the 2025 Annual General Shareholders’ Meeting.
  10. Approved appointment of the Company’s Chief Scientific Officer.
  11. Approved reassignment of the Company’s representative to serve as an institutional director of the subsidiary, Amaran Biotechnology, Inc.
  12. Approved reassignment of the Company’s representative to serve as an institutional director of the Australian subsidiary, OBI Pharma Australia Pty Ltd.
  13. Approved reassignment of the Company’s representative to serve as an institutional director of AP Biosciences, Inc.
  14. Approved appointment of the Chief Medical Officer of the US subsidiary.
  15. Approved promotion of the Company’s Director of Product Development Team.
  16. Approved the Company’s proposal for the second issuance roster of employee stock options for 2025.
2025-06-27 - The 1st of the 8th session
  1. Approved election for the 8th Chairperson of the Board.
  2. Approved election for the 5th Audit and Risk Management Committee Members and the 6th Remuneration and Nomination Committee Members.
  3. Approved election for the 1st Sustainable Development Committee Members.